Ser713
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser713  -  STAT4 (human)

Site Information
SDSTEPHsPSDLLPM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 50800612

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 )
Relevant cell line - cell type - tissue:
breast ( 2 ) , CD4+ (T lymphocyte) ( 1 ) , HEK293T (epithelial) ( 1 ) , MEF (fibroblast) ( 1 )

Upstream Regulation
Treatments:
LIF ( 1 )

Downstream Regulation
Effects of modification on STAT4:
enzymatic activity, inhibited ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, inhibited ( 1 )
Inhibit interaction with:
LIFR (human) ( 1 )

References 

1

Zhang YS, et al. (2019) STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation. EMBO J 38
30770344   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info